Market is huge:
Arthritis is the most common cause of disability in the United States, limiting the activities of nearly 21 million adults.
LODOTRA is a proprietary programmed-release formulation of low-dose prednisone and has received regulatory approval for the treatment of moderate to severe active rheumatoid arthritis (RA) when accompanied by morning stiffness in Europe where it is promoted by Mundipharma. LODOTRA utilizes SkyePharma's proprietary Geoclock™ technology.
Insiders and institutions-- Net institutional purchases in the current quarter at 2.3M shares, which represents about 9.07% of the company's float of 25.35M shares. Over the last six months, insiders were net buyers of 1,511,150 shares, which represents about 5.96% of the company's 25.35M share float.
From various sources:
***lodotra already approved in EU
***private placement was done at 3.62
+ warrants for .25 shrs, exercise 4.308
***generic threat put off for 30 months
***has partner, Mundipharma, and new manufacturing in Canada
***they announced expansion into latin america
***outperform or accumulate ratings(2) price targets $10 and $16
***insiders buying at higher prices
***for me this is a mid-term swing
I think we will see significantly higher price before 7/27.